Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2022 1
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Urinary TIMP-2*IGFBP-7 to diagnose acute kidney injury in children receiving cisplatin.
Chui H, McMahon KR, Rassekh SR, Schultz KR, Blydt-Hansen TD, Mammen C, Pinsk M, Cuvelier GDE, Carleton BC, Tsuyuki RT, Ross CJD, Devarajan P, Huynh L, Yordanova M, Crépeau-Hubert F, Wang S, Cockovski V, Palijan A, Zappitelli M; Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Research Study Group. Chui H, et al. Pediatr Nephrol. 2024 Jan;39(1):269-282. doi: 10.1007/s00467-023-06007-8. Epub 2023 Jun 26. Pediatr Nephrol. 2024. PMID: 37365422
At EV, pre-infusion biomarker concentrations had the highest area under the curves (AUC) (range: 0.61-0.62) for AKI diagnosis; at LV, biomarkers measured post-infusion and near discharge yielded the highest AUCs (range: 0.64-0.70). CONCLUSIONS: TIMP-2*IGFBP-7 were p …
At EV, pre-infusion biomarker concentrations had the highest area under the curves (AUC) (range: 0.61-0.62) for AKI diagnosis; at LV, …
Epidemiologic Characteristics of Acute Kidney Injury During Cisplatin Infusions in Children Treated for Cancer.
McMahon KR, Rassekh SR, Schultz KR, Blydt-Hansen T, Cuvelier GDE, Mammen C, Pinsk M, Carleton BC, Tsuyuki RT, Ross CJD, Palijan A, Huynh L, Yordanova M, Crépeau-Hubert F, Wang S, Boyko D, Zappitelli M; Applying Biomarkers to Minimize Long-term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Research Study Group. McMahon KR, et al. JAMA Netw Open. 2020 May 1;3(5):e203639. doi: 10.1001/jamanetworkopen.2020.3639. JAMA Netw Open. 2020. PMID: 32383745 Free PMC article.
Tubular Injury Biomarkers to Predict Chronic Kidney Disease and Hypertension at 3-Months Post-Cisplatin in Children.
Huang RS, McMahon KR, Wang S, Chui H, Lebel A, Lee J, Cockovski V, Rassekh SR, Schultz KR, Blydt-Hansen TD, Cuvelier GDE, Mammen C, Pinsk M, Carleton BC, Tsuyuki RT, Ross CJD, Palijan A, Zappitelli M; Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Research Study Group*. Huang RS, et al. Kidney360. 2024 Apr 26. doi: 10.34067/KID.0000000000000448. Online ahead of print. Kidney360. 2024. PMID: 38668904 Free article.
BACKGROUND: Urine kidney injury biomarkers measured during cisplatin therapy may identify patients at risk for adverse subsequent kidney outcomes. ...METHODS: We analyzed data from the Applying Biomarkers to Minimize Long-Term Effects of …
BACKGROUND: Urine kidney injury biomarkers measured during cisplatin therapy may identify patients at risk for adverse subsequent kid …
Acute kidney injury during cisplatin therapy and associations with kidney outcomes 2 to 6 months post-cisplatin in children: a multi-centre, prospective observational study.
McMahon KR, Lebel A, Rassekh SR, Schultz KR, Blydt-Hansen TD, Cuvelier GDE, Mammen C, Pinsk M, Carleton BC, Tsuyuki RT, Ross CJD, Huynh L, Yordanova M, Crépeau-Hubert F, Wang S, Palijan A, Lee J, Boyko D, Zappitelli M; Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Research Study Group. McMahon KR, et al. Pediatr Nephrol. 2023 May;38(5):1667-1685. doi: 10.1007/s00467-022-05745-5. Epub 2022 Oct 19. Pediatr Nephrol. 2023. PMID: 36260162